Integrating immunity and genetics in Follicular Lymphoma to establish a prognostic score fit for the modern era

将滤泡性淋巴瘤的免疫和遗传学结合起来，建立适合现代时代的预后评分

• 批准号: nhmrc : 1142980
• 负责人: A/Pr Claire Vajdic
• 金额: $ 93.12万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/integrating-immunity-genetics-modern-era/1319836
• 关键词: Integrating; immunity; genetics; Follicular; Lymphoma

Follicular lymphoma (FL) is divided into early and advanced stages. Early stage FL is frequently cured, but there is no way to identify who will be cured and who won't. By contrast advanced stage FL is incurable. Our unique access to well-annotated clinical trial and population based cohorts allows us to perform a detailed biological comparison of early and advanced FL, to gain a deeper understanding of the impediments to eradicating the disease, and to predict outcome to conventional therapy.

滤泡性淋巴瘤分为早期和晚期。早期FL经常被治愈，但没有办法确定谁将被治愈，谁不会。相比之下，晚期FL是无法治愈的。我们独一无二地获得注解良好的临床试验和基于人群的队列，使我们能够对早期和晚期FL进行详细的生物学比较，对根除疾病的障碍有更深入的了解，并预测常规治疗的结果。